BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12720142)

  • 21. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
    Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
    Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
    Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
    Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
    Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
    Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
    Sajid R; Siddiqui SH; Shaikh U; Adil S
    Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
    Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
    Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
    Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
    García-Sanz R; Ocio E; Caballero A; Magalhães RJ; Alonso J; López-Anglada L; Villaescusa T; Puig N; Hernández JM; Fernández-Calvo J; Aguilar A; Martín A; López R; Paiva B; Orfao A; Vidriales B; San-Miguel JF; Del Carpio D
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):168-71. PubMed ID: 21856552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of Waldenstrom's macroglobulinemia.
    McDermott MK; Bell EM
    Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies.
    Morra E; Cesana C; Klersy C; Barbarano L; Miqueleiz S; Varettoni M; Lucchesini C; Ricci F; Lazzarino M
    Clin Lymphoma; 2005 Mar; 5(4):265-9. PubMed ID: 15794862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of an animal model for Waldenström's macroglobulinemia.
    Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
    Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
    Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
    Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
    Ocio EM; Schop RF; Gonzalez B; Van Wier SA; Hernandez-Rivas JM; Gutierrez NC; Garcia-Sanz R; Moro MJ; Aguilera C; Hernandez J; Xu R; Greipp PR; Dispenzieri A; Jalal SM; Lacy MQ; Gonzalez-Paz N; Gertz MA; San Miguel JF; Fonseca R
    Br J Haematol; 2007 Jan; 136(1):80-6. PubMed ID: 17222197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
    Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
    Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial.
    Huynh BC; Rovner A; Rich MW
    Arch Intern Med; 2006 Sep; 166(17):1892-8. PubMed ID: 17000947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
    Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.